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AbstrACt
Objectives The aim of this Delphi survey was to 
establish an international consensus on the most useful 
outcome measures for research on the effectiveness of 
non- pharmacological interventions for migraine. This is 
important, since guidelines for pharmacological trials 
recommend measuring the frequency of headaches with 
50% reduction considered a clinically meaningful effect. 
It is unclear whether the same recommendations apply 
to complementary (or adjunct) non- pharmacological 
approaches, whether the same cut- off levels need to be 
considered for effectiveness when used as an adjunct 
or stand- alone intervention, and what is meaningful to 
patients.
setting University- initiated international survey.
Participants The expert panel was chosen based on 
publications on non- pharmacological interventions 
in migraine populations and from personal contacts. 
35 eligible researchers were contacted, 12 agreed 
to participate and 10 completed all 3 rounds of the 
survey. To further explore how migraine patients viewed 
potential outcome measures, four migraine patients were 
interviewed and presented with the same measurement 
tools as the researchers.
Procedures The initial Delphi round was based on a 
systematic search of the literature for outcome measures 
used in non- pharmacological interventions for headache. 
Suggested outcome measures were rated by each expert, 
blinded towards the other members of the panel, for its 
usefulness on a 5- point Likert scale ranging from definitely 
not useful to extremely useful. Results were combined 
using median values and IQRs. Tools rated overall as 
definitely or probably not useful were excluded from 
subsequent rounds. Experts further suggested additional 
outcome measures that were presented to the panel 
in subsequent rounds. Additionally, experts were asked 
to rank the most useful tools and provide information 
on feasible cut- off levels for effectiveness for the three 
highest ranked tools.
results Results suggest the use of the Migraine Disability 
Assessment (MIDAS), Headache Impact Test (HIT-6) and 
headache frequency as primary outcome measures. 
Patient experts suggested the inclusion of a measure of 
quality of life and evaluation of associated symptoms and 
fear of attacks.
Conclusions Recommendations are for the use of the 
MIDAS, the HIT-6 and headache frequency, in combination 
with an outcome measure for quality of life. Associated 
symptoms and fear of attacks should also be considered 
as secondary outcomes, if relevant for the individual target 
population. The cut- off level for effectiveness should be 
lower for non- pharmacological interventions, especially 
when used as an adjunct to medication.
trial registration number German Register of Clinical 
Trials (DRKS00011777)
IntrOduCtIOn
Migraine is a prevalent1 2 and disabling condi-
tion,3 with high socioeconomic costs mainly 
due to days off work.4–9 Migraine may become 
chronic when it occurs on ≥15 days per month 
for at least 3 months with features of migraine 
in ≥8 days.10
Guidelines for chronic and frequent 
episodic migraine recommend the use of non- 
pharmacological approaches as an adjunct 
strengths and limitations of this study
 ► This manuscript provides an international expert 
consensus on outcome measures for trials evalu-
ating the effectiveness of a non- pharmacological 
intervention for the reduction of migraine symptoms.
 ► A Delphi survey with three rounds was conducted to 
reach a consensus.
 ► Additional patient experts views contributed to a 
broader understanding on useful outcome mea-
sures including aspects of quality of life and attack- 
associated fear.
 ► A limitation is that patients were not included in 
the Delphi process but interviewed on a separate 
occasion.
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or alternative to the first- line pharmacological manage-
ment.11–16 Patients welcome this recommendation and 
usually report the use of complementary interventions to 
reduce the amount of acute pain medication.17 18 Espe-
cially, those patients who do not tolerate acute and/or 
prophylactic medicine because of side effects, have contra-
indications due to co- morbidities or may wish to avoid 
medication for other reasons, seek non- pharmacological 
alternatives.19 20 Recommended strategies include relax-
ation, cognitive- behavioural interventions and aerobic 
exercise; other interventions are mentioned but not 
recommended due to a lack of evidence for their effec-
tiveness,11–16 primarily due to methodological shortcom-
ings.21 22
Additional research is urgently needed to identify 
whether these other non- pharmacological treatment 
strategies are effective to complement pharmacological 
management as an adjunct or, in cases where patients do not 
tolerate acute and/or prophylactic medications because 
of side effects, have contraindications due to co- morbidi-
ties of other diseases or wish to avoid medication for other 
reasons, can manage their frequent episodic or chronic 
migraines prophylactically. However, before determining 
the effectiveness of either intervention, it is important to 
decide which outcome measures may be useful to indicate 
change following a non- pharmacological intervention in 
migraine patients. The International Headache Society 
(IHS) recommends the use of headache frequency as 
the primary outcome measure, usually assessed as head-
ache days per month documented in a headache diary.23 
However, this recommendation refers to studies investi-
gating the effect of preventive medication. A guideline 
for behavioural trials confirms frequency as the primary 
outcome measure.24 No other clinical guidelines deter-
mining the main outcome for primary headache disor-
ders exist for non- pharmacological trials. Additionally, no 
study has investigated whether the number of headache 
days is an improvement which is meaningful to patients. 
Therefore, it is unclear whether clinical trials investi-
gating the effectiveness of treatments such as massage, 
passive mobilisation or manipulation, physical activity 
or any other non- pharmacological intervention as an 
adjunct or as a stand- alone intervention should also use 
headache frequency as a primary outcome measure, and 
at what cut- off level the intervention can be considered 
successful.
The cut- off level stated by the IHS and the guideline 
for behavioural treatment for the effectiveness of a treat-
ment is a reduction of ≥50% of headache frequency.23 24 
Both guidelines, however, acknowledge that these levels 
might be lowered for studies on chronic migraine popula-
tions or reported as ‘somewhat improved’ if a responder 
rate >25% is reached. Non- pharmacological interven-
tions have a low risk of adverse events (AEs) and are less 
expensive. Intuitively, these approaches should therefore 
not be measured on the same scale as preventive medi-
cation since medication has a high risk of AEs. To reach 
a 50% level of improvement is particularly unrealistic if 
non- pharmacological interventions are evaluated as an 
add- on to the pharmacological management, especially 
since the net effect would then need to reach 75%.
The objective for this Delphi survey was to estab-
lish an international consensus on the most useful 
outcome measures for assessing the effectiveness of non- 
pharmacological interventions for frequent episodic or 
chronic migraine. A secondary aim of the Delphi study 
was to investigate whether the same level of improve-
ment, that is, ≥50% in headache frequency, is required to 
conclude on its effectiveness as recommended for preven-
tative migraine medication, when used as an adjunct or a 
stand- alone intervention.
MethOds
study design
The methods for this Delphi survey were based on 
published guidelines25 as well as on previous research.26 
The data collection was conducted between October 
2016 and August 2017. Selection of experts was based 
on personal contacts and a systematic search for primary 
authors in peer- reviewed journals on non- pharmacological 
intervention studies in headache populations. It must be 
noted that there is no guideline to define who is an expert 
for a Delphi survey or how many experts are required.27 
Participants remained anonymous during all rounds to 
allow the expression of their opinions without the influ-
ence of dominant characters.28 After the final round, all 
experts were invited to co- author the report and subse-
quently received a first draft for revision and a final draft 
for approval prior to submission. The survey procedures 
were predesigned and included the following steps:
I. The initial survey was guided by a systematic evalu-
ation of the literature on non- pharmacological inter-
ventions for migraine. PubMed was searched for articles 
published prior to 01.04.2017 using the following search 
strategy:
((((headache [Title/Abstract] OR migraine [Title/
Abstract])) AND ((aerobic training or sports or exer-
cise or acupuncture or chiropractic spinal manipulative 
therapy or progressive muscle relaxation or behavioural 
migraine management or cognitive behavioural therapy 
or biofeedback or physical activity or transcutaneous elec-
trical nerve stimulation)) AND adult Filters: Humans.
II. In the first Delphi round, experts were asked to rate 
the usefulness of the outcome measures identified in step 
1 for the use in non- pharmacological trials for frequent 
episodic or chronic migraine, on a 5- point Likert scale 
(1=‘extremely useful’, 2=’useful’, 3=‘do not know’, 
4=‘probably not useful’, 5=‘definitely not useful’). Experts 
were further invited to provide and suggest additional 
outcome measurement tools that they also considered 
relevant. To allow for an informed decision on test prop-
erties and previous application in research, references 
were provided for each outcome measure. To promote 
a more reliable decision on outcome measures, experts 
were additionally asked to rank their three favourite tools 
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Figure 1 Results from the initial survey round. HDI, Henry 
Ford disability index; HIT-6, Headache impact test; McGill, 
McGill Pain Questionnaire; MIDAS, Migraine Disability 
Assessment Scale; NRS, Numerical Rating Scale; PDI, Pain 
Disability Index; SF-36, Short Form 36.
in a hierarchical order and to provide the cut- off levels 
for effectiveness which they perceived feasible for non- 
pharmacological interventions for frequent episodic or 
chronic migraine. The questionnaire used for the rating 
procedure was sent as a word document via email after 
it had been tested among working group members for 
comprehensibility. If individual ratings were missing or 
questionnaires were not returned, reminder emails were 
sent.
III. For the second round, group responses were anal-
ysed and fed back to the experts (via email) including 
the new tests suggested. These were again rated for their 
usefulness as in round one. To provide more information 
on the specific tools, experts were invited to comment on 
the individual tools.
IV. A third round was conducted in the same manner 
as the second round to include all new information that 
emerged from round two and to reach a final agreement.
V. Definition of consensus: no further rounds are 
conducted if no new outcome measures are suggested. 
Median values across experts were used to identify the 
most useful tools. Consensus on the relevance of an 
outcome measure was assumed if 75% of the participants 
rated the tool as ‘useful’ or ‘extremely useful’. All outcome 
measures, rated as ‘definitely not useful’ or ‘probably not 
useful’ were excluded from subsequent Delphi rounds 
(based on the median value across experts). If multiple 
tools meet this definition of consensus, a hierarchical 
ranking was used to determine the tool considered most 
useful from the perspective of the experts in the panel.
data analysis
All tools were analysed using the median and IQR across 
ratings and presented in box plots. Hierarchical ranking 
was analysed by allocating the highest- ranking tool 50 
points, the second place 30 points and the third place 20 
points. Sums across all ratings for each tool were calcu-
lated to identify the highest- ranking outcome measure. 
Comments on the outcome measures were summarised 
in a table with general quotes provided by the experts and 
for each tool.
Patient and public involvement
No patient involvement. Patient’s views were expressed 
and integrated into the results as stated in the section on 
‘patients’ views’.
Patients’ views
Patients repeatedly stated that there was so much more 
to their suffering than the number of headache days in 
their diaries. Rather than including them in the Delphi 
process, patients were invited to take part as experts for 
their symptoms in this study by being interviewed. It was 
anticipated that patients’ views were more multifaceted 
and diverse and that the ranking tasks requested during 
the Delphi rounds would do their opinions not sufficient 
justice. Therefore, in order to include the preferences of 
the target group, four women, known to the researchers 
from the university headache clinic, diagnosed with 
chronic migraine with >10 years history of migraine 
were recruited into the study. They were experienced 
in pharmacological and non- pharmacological trials and 
knowledgeable on a wide range of outcome measures 
throughout their experiences at a specialised university 
outpatient headache clinic. Patients were presented with 
the same outcome measures as the research experts and 
interviewed regarding their preference and opinion on 
the different tools. They were further asked whether they 
regarded a≥50% change in the number of headache days 
as an acceptable outcome level of improvement to justify 
a non- pharmacological treatment. Two patients were 
interviewed as a group to stimulate discussion and two 
were interviewed by telephone. Interviews were held at 
the outpatient headache clinic at the University Medical 
Center Hamburg- Eppendorf.
The interviews were recorded on a digital voice 
recorder. After the interviews, two researchers transcribed 
the interviews independently on personal computers to 
avoid potential risks of mishearing and misinterpreta-
tion.29 Transcripts were compared and discussed before 
they were coded and analysed.
A thematic analysis approach was used by categorising 
questions, themes and quotations.30 To focus on the 
research question, only those quotations were chosen in 
which the participants explained their views about the 
outcome measures.
results
sample characteristics
A total of 35 international experts from seven countries 
were identified and invited via email to participate. The 
invitation included the researcher's details and meticu-
lous information about the survey and the study design. 
Twelve experts agreed to participate and completed the 
first round, and 10 experts completed all three rounds of 
the survey.
delphi round 1
The literature search identified seven different outcome 
measures used in studies evaluating the effectiveness of 
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non- pharmacological interventions in migraine popula-
tions: Henry Ford- Hospital Headache Disability Inven-
tory (HDI), Headache Impact Test (HIT-6), Migraine 
Disability Assessment (MIDAS), Numerical Rating Scale 
(NRS), Pain Disability Index (PDI), Short Form-36 
(SF-36) and Short Form McGill Pain Questionnaire (SF- 
MPQ). These instruments were evaluated by a panel of 
12 experts (eight physiotherapists, two chiropractors, two 
psychologists). All experts had an academic degree equiv-
alent to PhD except one expert with an MSc. From these 
seven initial tests, PDI and SF- MPQ showed a median value 
of 3 (rated by three and four experts, respectively, as ‘do 
not know’) while the remaining tests showed a median 
rating of 2 (‘useful’) (figure 1). No outcome measure 
was discharged after this initial round. The ranking task 
placed the MIDAS first, followed by the HIT-6 and the 
NRS by the experts.
Ten additional outcome measures were suggested 
by the experts: Brief Pain Inventory, Craniofacial Pain 
and Disability Inventory (CF- PDI), Functional Disability 
Inventory (FDI), Fragebogen zu Kopfschmerzmanage-
ment und Selbstwirksamkeit (FKMS), Headache Diary, 
Headache Frequency, Migraine Specific Quality of Life, 
Veterans RAND 12 Item Health Survey (VR-12), Rostocker 
Kopfschmerz- Fragenkomplex (RoKoKo) and DoloTest.
delphi round 2
These outcome measures were rated by the experts partic-
ipating in the second round (n=10). Two ratings (one on 
the RoKoKo and one on the FKMS) were missing. From 
the 10 newly evaluated outcome measures, headache 
diary and headache frequency received median ratings of 
‘extremely useful’, while CF- PDI and FDI were excluded 
as ‘definitely not useful’ and ‘probably not useful’, respec-
tively (figure 2). There is no English version available 
for the RoKoKo and the FKMS, making the feasibility 
of this tool not useful for English- speaking researchers. 
Comments provided by experts were summarised in a 
table with numbers behind quotes indicating the number 
of experts who expressed this opinion (table 1).
The revised ranking based on outcome measures from 
rounds one and two indicated that the MIDAS was the 
most useful tool, followed by the HIT-6 and the headache 
frequency. Headache diary, PDI and NPRS shared rank 
four. Suggested cut- off levels for each tool, indicating the 
acceptable effectiveness of a non- pharmacological inter-
vention when used as an adjunct treatment to medication 
or as a stand- alone intervention, are listed in table 2.
results from the patient interviews
All patients agreed that the SF-36 appeared to be the tool 
which best reflected their well- being. This was followed by 
the MIDAS, the HIT-6 and the HDI. The least useful tool 
from the patients’ point of view were NRS and McGill.
Patients commented that some aspects of their 
migraine were missing in the measuring tools available. 
One patient stated that sometimes her aura was the domi-
nant problem but that this was never mentioned as an 
option in any of the tools. Another patient suggested 
adding a measure for fear of the next migraine attack. 
The fear itself was sometimes more disabling than any 
other symptom for this patient.
When asked about the minimum relevant change 
levels acceptable, patients agreed that any improvement 
of any of their symptoms would justify seeking a non- 
pharmacological treatment. A 50% reduction of head-
ache days did not seem to be realistic for any patient for 
a non- pharmacological treatment. They explained how 
difficult it was to identify changes following a treatment 
because of the unpredictability of migraine. Quotations 
underlining the patients’ points of view are presented in 
table 3.
dIsCussIOn
The present study reports on an international Delphi 
survey, aiming to reach consensus on the measurement 
tools to be used in non- pharmacological interventions 
for migraine. MIDAS, HIT-6 and headache frequency 
reached the definition of consensus and were ranked 
as the most relevant tools by the Delphi participants; 
conversely, patients valued measures of quality of life 
higher and suggested to measure additional aspects such 
as fear of the next attack.
While the outcome measures that were suggested by 
experts in this study largely reflect those used in pharma-
cological trials, MIDAS and HIT-6 were prioritised over 
headache frequency, potentially indicating that aspects 
of suffering and disability were valued higher than the 
simple counting of headache days.
Expert opinions varied widely with most outcome 
measures receiving ratings ranging from ‘extremely useful’ 
to ‘probably or definitely not useful’, indicating that none 
of the suggested outcome measures was perceived as ideal. 
This is partially explained by comments from experts 
and two of the four patients stating that the MIDAS is 
often misunderstood and not answered correctly and 
should be simplified. Furthermore, recalling a 3- month 
period might introduce bias and reduce precision of the 
measurement. The general criticism about the HIT-6 was 
that it does not accommodate the complexity of migraine 
and its impact on individuals. To prevent researchers 
from using different tools in future research and thereby 
not allowing for the comparability of results, these limita-
tions should be addressed by, for example, providing a 
version of the MIDAS only reflecting on the past 4 weeks 
rather than on the past 3 months.
The highest rated outcome measures also reflected 
those best evaluated in the literature. MIDAS has been 
validated and translated in many languages31–36 and 
has shown good psychometric properties.31–39 Similar 
research is available on HIT-6.34 40–43 Some of the tools 
suggested were too specific for a particular pathology, 
such as the CF- PDI and FDI and are therefore only appli-
cable in situations when painful temporomandibular 
dysfunctions play a dominant role. Others were too broad 
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Table 1 Expert statements on outcome measures
Outcome 
measure Expert statement
Ranking 
after final 
round
MIDAS  ► Useful tool for measuring disability (2)
 ► Difficult to use it for non- pharmacological interventions (3)
 ► Should be simplified (1)
1
HIT-6  ► Short and simple to complete (1)
 ► Disease- specific and includes functional and emotional disability (1)
 ► Criticised for ‘its ability to identify the complexity of impact with which headache has on individuals’ (2)
 ► In clinical practise this questionnaire is the most representative for change in headache frequency related to impact on 
daily life (1)
2
Headache 
frequency
 ► Difference to diaries? (1)
 ► Primary efficacy outcome measurement in the first, second and third IHS clinical trial guideline, thus, it is highly relevant (1)
3
NPRS  ► Very important measurement (1)
 ► Not useful (for headache) (3)
 ► Unlikely to capture the overall impact of headache (1)
 ► Depends on self- report (1)
4
PDI  ► Not specific for headache (4)
 ► Too general and too broad (1)
 ► There is not cut- off point on what is defined as disability (1)
4
Headache 
diary
 ► Number 1 in research for chronic (migraine) headache (1)
 ► Headache diaries are extremely effective in monitoring headache and migraine patients in terms of efficacy outcomes. (1)
4
HDI  ► Time consuming (2)
 ► Good tool for measuring (perception) of disability (2)
 ► Poorly validated (1)
5
SF-36  ► Most useful tool for measuring general disability (4)
 ► Not specific for headache/migraine (5)
 ► Takes time to fill out (1)
6
FKMS  ► Unknown (2)
 ► Probably not an outcome scale (1)
7
CF- PDI  ► Not familiar (1)
 ► Specific for craniomandibular dysfunction not for headaches (2)
7
Dolo- test  ► The DoloTest has been tested on headache patients with regards to measuring pain and quality of life and was found to 
be valuable. The questionnaire also contains clear measuring with visual analogue scale (VAS) for each of the 8- items (1)
 ► However, there seem to be a financial interest behind the technological constructions and interpretation which leads to 
question the applicability (1)
 ► Also, the items probably only duplicate other validated tests for pain and quality of life (1)
7
Migraine 
specific 
quality of 
life
 ► Important questionnaire to measure impact of migraine on daily life (2) 8
VR 12  ► Not a specific headache related questionnaire, but shows an insight in general health and well- being (3) 8
SF- MPQ  ► Not useful in headache/migraine (5)
 ► Takes a lot of time and explanations (1)
 ► Does not identify disability or the impact of headache on daily life (1)
8
FDI  ► Not useful for chronic migraine, because it is focused on problems related to cranio- mandibular dysfunction (3) 8
RoKoKo  ► Could not locate the English version (1) 8
BPI  ► Could be useful for patients with chronic migraine (1)
 ► This questionnaire was developed for patients with cancer- the psychometric properties are not known for headache (1)
 ► Not all questions are relevant to headache (1)
 ► Not migraine- specific although it contains a few relevant questions (1)
8
Numbers behind statements indicate the number of experts expressing this opinion.
BPI, Brief Pain Inventory; CF_PDI, Craniofacial Pain and Disability Inventory; FDI, Functional Disability Inventory; FKMS, Fragebogen zu Kopfschmerzmanagement 
und Selbstwirksamkeit; HDI, Henry Ford Disability Index; HIT-6, Headache Impact Test; IHS, International Headache Society; McGill, McGill Pain Questionnaire; 
MIDAS, Migraine Disability Assessment Scale; MSQ, Migraine Specific Quality of Life; NPRS, Numerical Pain Rating Scale; NRS, Numerical rating Scale; PDI, Pain 
Disability Index; RoKoKo, Rostocker Kopfschmerz- Fragenkomplex; SF-36, Short Form 36; VAS, Visual Analog Scale; VR-12, Veterans RAND 12 Item Health Survey.
such as the SF-36 or VR-12 or PDI and therefore not 
considered as a specific outcome measure for studies on 
migraine. This might also be the reason, why no global 
rating tool, such as Patient Global Rating of Change was 
suggested or discussed by experts. Interestingly, patients 
viewed this topic differently by stating a clear preference 
for the SF-36. Patients also commented that the associ-
ated symptoms can be more disabling than the head-
ache itself, such as the aura or fear of the next migraine 
attack. The migraine- specific quality of life questionnaire 
covers fear of the next attack and has been evaluated in 
various languages.44–50 It was initially unclear why the tool 
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Figure 2 Results from the second survey round. BPI, 
Brief Pain Inventory; CF_PDI, Craniofacial Pain and 
Disability Inventory; FDI, Functional Disability Inventory; 
FKMS, Fragebogen zu Kopfschmerzmanagement und 
Selbstwirksamkeit; MSQ, Migraine Specific Quality of Life; 
RoKoKo, Rostocker Kopfschmerz- Fragenkomplex; VR-12, 
Veterans RAND 12 Item Health Survey.
Table 2 Suggested cut- off levels to indicate effectiveness
Outcome measure
Suggested cut- off levels to 
indicate effectiveness
HIT-6
Max. score 78 points
 ► 25% (1)
 ► 30% (1)
 ► 50% (1)
 ► 8 points (1)
 ► 10 points (1)
 ► 6–8 points (1)
MIDAS
Max. score 270 points
 ► 10 points (2)
 ► 20 points (2)
 ► 25% (1)
Headache frequency
Max. score 30/31 points
 ► 50% (2)
 ► 25% (1)
The numbers behind the cut- off levels indicate the number of 
experts recommending this cut- off level.
Hit-6, Headache Impact Test; MIDAS, Migraine Disability 
Assessment Scale.
was not popular with the experts in this study. Few had 
used it because although free for researchers, it is only 
available from the company GlaxoSmithKline and the 
included 25 items require more time than the MIDAS or 
the HIT-6. Fear of migraine can also be investigated by 
a 4- item tool which has recently been developed.51 This 
tool has not been used in previous published trials on 
non- pharmacological treatments and was not suggested 
by the Delphi panel. Associated symptoms have largely 
been ignored in research. Wang et al recently reported on 
the development of a tool to capture these symptoms, but 
psychometric properties and testing procedures are not 
yet available.52
The commonly agreed cut- off value for effectiveness in 
pharmacological trials is a ≥50% reduction in headache 
days53 with an accepted reduction to a responder rate of 
30% in chronic migraine populations.23 Previous research 
has identified the minimal clinically relevant change for 
HIT-6 to be −2.5 to −6 points in migraine.42 No recommen-
dation was identified for the MIDAS. A ≥50% reduction 
of headache frequency is a target that is difficult to reach 
with non- pharmacological interventions, especially 
when provided as an adjunct to preventive medication 
and especially in chronic migraine. Lowering the target 
should be considered, especially since AEs are few, mild 
and transient,54 and most of the interventions are low 
cost. However, based on the expert panel of this survey, 
there was no clear agreement on a specific cut- off level for 
any of the tools, but it seems that more realistic targets are 
needed to show the true effect of a non- pharmacological 
intervention. A limitation of the survey design was that 
cut- off levels for effectiveness were not distinguished for 
studies using non- pharmacological interventions as an 
adjunct treatment to, for example, prophylactic medica-
tion and studies using non- pharmacological interventions 
as a stand- alone treatment. However, in both situations a 
lower target should be used, since non- pharamcological 
interventions do not (or to a much lower extent) have 
to consider the trade- off between effect and side- effects. 
Patients confirmed that any small improvements of any of 
their symptoms would justify the time and money spent 
on the intervention.
For future research on non- pharmacological inter-
ventions for frequent episodic or chronic migraine, 
it is highly important to use the same primary and/or 
secondary outcome measure to be able to compare and 
combine results to reach a higher level of evidence that 
can subsequently be included in national and interna-
tional guidelines. At this stage, there does not seem to 
be an ideal outcome measure. Neither does it seem to 
be clear which aspects of migraine (such as its intensity, 
its impact on a person’s life, it’s uncertainty…) are the 
most important aspects to be measured. Within these 
limitations and with the literature currently available, we 
promote the use of the MIDAS, the HIT-6 and headache 
frequency, and an outcome measure for quality of life 
(eg, SF-36), which was preferred by patients and recently 
identified as a useful indicator for change,55 in addition 
to the newest clinical guideline recommendations by 
the IHS53 when conducting future non- pharmacological 
randomised clinical trials in patients with frequent 
episodic or chronic migraine. Associated symptoms 
and fear of attacks should be considered as secondary 
outcomes.
We recognise some potential limitations of the current 
study. First, there was a limited number of experts avail-
able to complete all three rounds of the Delphi process. 
However, they represented different professional back-
grounds and reflect the variability in non- pharmacological 
migraine- research. Only four patients were interviewed; 
these were chosen based on their longstanding migraine 
history and previous participation in research trials, thus, 
acquiring a high level of expertise on outcome measures in 
relation to their own suffering levels. Outcome measures 
were presented to experts in a non- randomised order. 
While this might influence responses, it also helped to 
keep experts oriented by using a standardised order of 
outcome measures and response options.
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Table 3 Patient perspective on suggested outcome measures
Questions Themes Quotations
What is your first 
impression of the 
measuring tools?
MIDAS “…MIDAS is very common”
“3 months is a difficult period of time to remember, symptoms can vary from month to 
month”
  HDI / HIT-6 “….I quite liked this one”
“…as well as the HIT-6”
  NPRS “some measures are just numbers, NRS does not measure anything, really”
  McGill “this only looks at pain quality but not at frequency, this is strange”
  Headache 
frequency / 
diary
“when a new study is published I always look at the reduction of days per month, so it 
does seem important to count days”
  SF36 “I liked the SF-36 best, because it includes quantity but also measures the burden of 
migraine…and how I am”
What do you like / 
dislike about these 
tools?
Aura “sometimes my aura is worse than the headache, but this is never asked in any of the 
questionnaires”
  Pain “and sometimes we are asked about the duration of the attack, which is stupid, 
because I am taking my medication and the headache is gone. I cannot say how it 
would have continued without the medication”
“I am usually asked whether my headache is on the right or left or both sides, but 
I cannot often locate it precisely. It changes and is sometimes in my forehead and 
sometimes in the back and the whole head hurts. Am I the only one who finds this 
difficult?”
  Fear “I am always scared of the next attack - This fear is sometimes stronger than on 
other days. I sometimes feel as if the fear is worse than the actual attack, because it 
influences more or less every day of my life.”
Is a 50% reduction 
of headache days 
realistic?
  “(…) I currently have more frequent migraine attacks but the pain is not as intense as it 
was. My aura, however, is more intense than ever, it sometimes occurs on 15 days in 
1 month. I have also had months with only 3 days of aura and more headache. I find it 
very difficult to estimate whether an intervention was effective because of this variability 
in symptoms. The effect probably needs to be followed up over 2 years to identify 
whether the reduction was one of the usual variations.”
“If any medication would give me 20% reduction of symptoms I would be very very 
happy! Any reduction is good!”
HDI, Henry Ford Disability Index; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment Scale; NRS, Numerical rating Scale.
COnClusIOn
There was some diversity between experts’ and patients’ 
opinions on the most important outcome measures for 
non- pharmacological trials. Recommendations are for 
the use of the MIDAS, the HIT-6 and headache frequency, 
in combination with an outcome measure for quality of 
life. Associated symptoms and fear of attacks should also 
be considered as secondary outcomes, if relevant for 
the individual target population. The cut- off level for 
effectiveness might be lower for non- pharmacological 
trials, especially when these are used as an adjunct to 
medication.
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